BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ichikawa H, Mikami K, Okada T, Yamashita Y, Ishizaki Y, Tomoda A, Ono H, Usuki C, Tadori Y. Aripiprazole in the Treatment of Irritability in Children and Adolescents with Autism Spectrum Disorder in Japan: A Randomized, Double-blind, Placebo-controlled Study. Child Psychiatry Hum Dev 2017;48:796-806. [PMID: 28004215 DOI: 10.1007/s10578-016-0704-x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 8.8] [Reference Citation Analysis]
Number Citing Articles
1 Shafiq S, Pringsheim T. Using antipsychotics for behavioral problems in children. Expert Opinion on Pharmacotherapy 2018;19:1475-88. [DOI: 10.1080/14656566.2018.1509069] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
2 Persico AM, Ricciardello A, Cucinotta F. The psychopharmacology of autism spectrum disorder and Rett syndrome. Psychopharmacology of Neurologic Disease. Elsevier; 2019. pp. 391-414. [DOI: 10.1016/b978-0-444-64012-3.00024-1] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
3 Lambrechts S, Devriendt K, Vogels A. Low-Dose Aripiprazole and Risperidone for Treating Problem Behavior in Children With Pitt-Hopkins Syndrome. J Clin Psychopharmacol 2018;38:260-1. [PMID: 29596149 DOI: 10.1097/JCP.0000000000000871] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Goltz J, Ivanov I, Rice TR. Second generation antipsychotic-induced weight gain in youth with autism spectrum disorders: a brief review of mechanisms, monitoring practices, and indicated treatments. Int J Dev Disabil 2019;67:159-67. [PMID: 34188897 DOI: 10.1080/20473869.2019.1638583] [Reference Citation Analysis]
5 Alsayouf HA, Talo H, Biddappa ML, Qasaymeh M, Qasem S, De Los Reyes E. Pharmacological Intervention in Children with Autism Spectrum Disorder with Standard Supportive Therapies Significantly Improves Core Signs and Symptoms: A Single-Center, Retrospective Case Series. Neuropsychiatr Dis Treat 2020;16:2779-94. [PMID: 33235453 DOI: 10.2147/NDT.S277294] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Goel R, Hong JS, Findling RL, Ji NY. An update on pharmacotherapy of autism spectrum disorder in children and adolescents. International Review of Psychiatry 2018;30:78-95. [DOI: 10.1080/09540261.2018.1458706] [Cited by in Crossref: 56] [Cited by in F6Publishing: 33] [Article Influence: 14.0] [Reference Citation Analysis]
7 Novell R, Esteba-Castillo S, Rodriguez E. Efficacy and safety of a GABAergic drug (Gamalate® B6): effects on behavior and cognition in young adults with borderline-to-mild intellectual developmental disabilities and ADHD. Drugs Context 2020;9:212601. [PMID: 32158489 DOI: 10.7573/dic.212601] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
8 Rodrigues R, Lai M, Beswick A, Gorman DA, Anagnostou E, Szatmari P, Anderson KK, Ameis SH. Practitioner Review: Pharmacological treatment of attention‐deficit/hyperactivity disorder symptoms in children and youth with autism spectrum disorder: a systematic review and meta‐analysis. J Child Psychol Psychiatr 2021;62:680-700. [DOI: 10.1111/jcpp.13305] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 D'Alò GL, De Crescenzo F, Amato L, Cruciani F, Davoli M, Fulceri F, Minozzi S, Mitrova Z, Morgano GP, Nardocci F, Saulle R, Schünemann HJ, Scattoni ML; ISACA Guideline Working Group. Impact of antipsychotics in children and adolescents with autism spectrum disorder: a systematic review and meta-analysis. Health Qual Life Outcomes 2021;19:33. [PMID: 33494757 DOI: 10.1186/s12955-021-01669-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Guinchat V, Cravero C, Lefèvre-Utile J, Cohen D. Multidisciplinary treatment plan for challenging behaviors in neurodevelopmental disorders. Handb Clin Neurol 2020;174:301-21. [PMID: 32977887 DOI: 10.1016/B978-0-444-64148-9.00022-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
11 Coustals N, Ménard ML, Cohen D. Aripiprazole in Children and Adolescents. J Child Adolesc Psychopharmacol 2021;31:4-32. [PMID: 32931315 DOI: 10.1089/cap.2020.0014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
12 Reurts EE, Troost PW, Dinnissen M, Reijnen S, Hoekstra PJ, Popma A. Aripiprazole in youth with intellectual disabilities: A retrospective chart study. J Intellect Disabil 2021;25:449-57. [PMID: 32181681 DOI: 10.1177/1744629520905175] [Reference Citation Analysis]
13 Limandri BJ. Clinical Use of Dopamine Modulators as Third-Generation Antipsychotic Agents. J Psychosoc Nurs Ment Health Serv 2019;57:7-11. [PMID: 30703220 DOI: 10.3928/02793695-20190116-02] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 Ichikawa H, Hiratani M, Yasuhara A, Tsujii N, Oshimo T, Ono H, Tadori Y. An open-label extension long-term study of the safety and efficacy of aripiprazole for irritability in children and adolescents with autistic disorder in Japan. Psychiatry Clin Neurosci 2018;72:84-94. [PMID: 28941259 DOI: 10.1111/pcn.12607] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
15 Wang F, Wen F, Yu L, Yan J, Liu J, Li Y, Cui Y. The efficacy and safety in attention deficit hyperactivity disorder of second-generation antipsychotics and other medications for hyperactivity in children and adolescents with autism: a meta-analysis. Int Clin Psychopharmacol 2021;36:109-16. [PMID: 33492013 DOI: 10.1097/YIC.0000000000000349] [Reference Citation Analysis]
16 Barcellos HHDA, Pompermaier A, Mendonça-soares S, Maffi VC, Fernandes M, Koakoski G, Kirsten K, Baldisserotto B, Barcellos LJG. Aripiprazole prevents stress-induced anxiety and social impairment, but impairs antipredatory behavior in zebrafish. Pharmacology Biochemistry and Behavior 2020;189:172841. [DOI: 10.1016/j.pbb.2019.172841] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Solmi M, Fornaro M, Ostinelli EG, Zangani C, Croatto G, Monaco F, Krinitski D, Fusar-Poli P, Correll CU. Safety of 80 antidepressants, antipsychotics, anti-attention-deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects. World Psychiatry 2020;19:214-32. [PMID: 32394557 DOI: 10.1002/wps.20765] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 15.5] [Reference Citation Analysis]
18 Kim H, Park E, Kim J, Boon-yasidhi V, Tarugsa J, Reyes A, Manalo S, Joung Y. Aripiprazole for Irritability in Asian Children and Adolescents with Autistic Disorder: A 12-Week, Multinational, Multicenter, Prospective Open-Label Study. Journal of Child and Adolescent Psychopharmacology 2018;28:402-8. [DOI: 10.1089/cap.2017.0152] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
19 D'Alò GL, De Crescenzo F, Amato L, Cruciani F, Davoli M, Fulceri F, Minozzi S, Mitrova Z, Morgano GP, Nardocci F, Saulle R, Schünemann HJ, Scattoni ML; ISACA guideline working group. Acceptability, equity, and feasibility of using antipsychotics in children and adolescents with autism spectrum disorder: a systematic review. BMC Psychiatry 2020;20:561. [PMID: 33238921 DOI: 10.1186/s12888-020-02956-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Sugimoto Y, Yamamura K, Takayama T, Fukuta Y, Aoki K, Mikami K, Tomoda A. Aripiprazole in the real-world treatment for irritability associated with autism spectrum disorder in children and adolescents in Japan: 52-week post-marketing surveillance. BMC Psychiatry 2021;21:204. [PMID: 33888067 DOI: 10.1186/s12888-021-03201-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Brandenburg C, Soghomonian JJ, Zhang K, Sulkaj I, Randolph B, Kachadoorian M, Blatt GJ. Increased Dopamine Type 2 Gene Expression in the Dorsal Striatum in Individuals With Autism Spectrum Disorder Suggests Alterations in Indirect Pathway Signaling and Circuitry. Front Cell Neurosci 2020;14:577858. [PMID: 33240045 DOI: 10.3389/fncel.2020.577858] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Maneeton N, Maneeton B, Putthisri S, Suttajit S, Likhitsathian S, Srisurapanont M. Aripiprazole in acute treatment of children and adolescents with autism spectrum disorder: a systematic review and meta-analysis. Neuropsychiatr Dis Treat 2018;14:3063-72. [PMID: 30519027 DOI: 10.2147/NDT.S174622] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.8] [Reference Citation Analysis]
23 Alfageh BH, Wang Z, Mongkhon P, Besag FMC, Alhawassi TM, Brauer R, Wong ICK. Safety and Tolerability of Antipsychotic Medication in Individuals with Autism Spectrum Disorder: A Systematic Review and Meta-Analysis. Pediatr Drugs 2019;21:153-67. [DOI: 10.1007/s40272-019-00333-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
24 Mikami K, Okazawa H, Kimoto K, Akama F, Onishi Y, Takahashi Y, Yamamoto K, Matsumoto H. Effect of Oral Iron Administration on Mental State in Children With Low Serum Ferritin Concentration. Glob Pediatr Health 2019;6:2333794X19884816. [PMID: 31696146 DOI: 10.1177/2333794X19884816] [Reference Citation Analysis]
25 Persico AM, Ricciardello A, Lamberti M, Turriziani L, Cucinotta F, Brogna C, Vitiello B, Arango C. The pediatric psychopharmacology of autism spectrum disorder: A systematic review - Part I: The past and the present. Prog Neuropsychopharmacol Biol Psychiatry 2021;110:110326. [PMID: 33857522 DOI: 10.1016/j.pnpbp.2021.110326] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
26 Hoshino K, Hayashi M, Ishizaki A, Kimura K, Kubota M, Nezu A, Yasuhara A. Very-Low-Dose Levodopa Therapy for Pediatric Neurological Disorders: A Preliminary Questionnaire in Japan. Front Pediatr 2021;9:569594. [PMID: 33748036 DOI: 10.3389/fped.2021.569594] [Reference Citation Analysis]
27 Fallah MS, Shaikh MR, Neupane B, Rusiecki D, Bennett TA, Beyene J. Atypical Antipsychotics for Irritability in Pediatric Autism: A Systematic Review and Network Meta-Analysis. Journal of Child and Adolescent Psychopharmacology 2019;29:168-80. [DOI: 10.1089/cap.2018.0115] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 8.0] [Reference Citation Analysis]
28 Ballester P, Espadas C, Londoño AC, Almenara S, Aguilar V, Belda C, Pérez E, Muriel J, Peiró AM. The challenge of detecting adverse events in adults with autism spectrum disorder who have intellectual disability. Autism Res 2021. [PMID: 34652075 DOI: 10.1002/aur.2624] [Reference Citation Analysis]
29 Simashkova NV, Makushkin EV, Ivanov MV, Balakireva EE, Kulikov AV, Koval-Zaytsev AA, Luss LA. [Models of clinical and social management of patients with autism spectrum disorders]. Zh Nevrol Psikhiatr Im S S Korsakova 2021;121:13-20. [PMID: 34283524 DOI: 10.17116/jnevro202112106113] [Reference Citation Analysis]
30 Bhandari R, Paliwal JK, Kuhad A. Dietary Phytochemicals as Neurotherapeutics for Autism Spectrum Disorder: Plausible Mechanism and Evidence. In: Essa MM, Qoronfleh MW, editors. Personalized Food Intervention and Therapy for Autism Spectrum Disorder Management. Cham: Springer International Publishing; 2020. pp. 615-46. [DOI: 10.1007/978-3-030-30402-7_23] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
31 Houghton R, van den Bergh J, Law K, Liu Y, de Vries F. Risperidone versus aripiprazole fracture risk in children and adolescents with autism spectrum disorders. Autism Res 2021;14:1800-14. [PMID: 34080319 DOI: 10.1002/aur.2541] [Reference Citation Analysis]
32 Zhou MS, Nasir M, Farhat LC, Kook M, Artukoglu BB, Bloch MH. Meta-analysis: Pharmacologic Treatment of Restricted and Repetitive Behaviors in Autism Spectrum Disorders. J Am Acad Child Adolesc Psychiatry 2021;60:35-45. [PMID: 32387445 DOI: 10.1016/j.jaac.2020.03.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]